MedTrace Logo

A Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of Topical ESR-114 in Subjects With Plaque Psoriasis

NCT03630939 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 104

Last updated 2020-07-29

No results posted yet for this study

Summary

This is a multicenter, double-blind, randomized, vehicle-controlled, parallel-group proof-of-concept study designed to assess the safety, tolerability, pharmacokinetics, and preliminary efficacy of topically applied ESR-114 following twice daily (BID) application for 42 days (6 weeks).

Conditions

  • Psoriatic Plaque

Interventions

DRUG

ESR-114

ESR-114 Topical Gel

OTHER

Placebo

Placebo Topical Gel

Sponsors & Collaborators

  • Innovaderm Research Inc.

    collaborator OTHER

  • Escalier Biosciences B.V.

    lead INDUSTRY

Principal Investigators

  • Allison Luo, MD · Escalier Biosciences B.V.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-08-09
Primary Completion
2019-06-05
Completion
2019-06-12
FDA Drug
Yes

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03630939 on ClinicalTrials.gov